Therapeutic Nuclear Medicines Market Worth Observing Growth Top Key Player- Bayer AG, Novartis AG, GE Healthcare, Curium Pharmaceuticals, Eckert & Ziegler and International Isotopes Inc.

www.futuremarketinsights.com I @futuremarketins I /company/future-market-insights
© 2019 Future Market Insights, All Rights Reserved
Therapeutic Nuclear Medicines Market Financial Guide
for 2028 by Leading Players- Bayer AG, Novartis AG, GE
Healthcare, Curium Pharmaceuticals and Others
Feb 2021 Report Id : REP-GB-2930
Published On : 14-Jan-2019
Category : Healthcare, Pharmaceuticals & Medical Devices

About
Future Market Insights
Future Market Insights (FMI) is a premier provider of syndicated research reports, custom
research reports, and consulting services. We deliver a complete packaged solution, which
combines current market intelligence, statistical anecdotes, technology inputs, valuable growth
insights, aerial view of the competitive framework, and future market trends.
We provide research services at a global as well as regional level; key regions include GCC,
ASEAN, and BRIC.
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy,
Technology, Healthcare, and Retail.
We have a global presence with delivery centers across India specializing in providing global
research reports and country research reports. FMI is headquartered out of London, U.K., with a
state-of-the-art delivery center located in Pune, India. We combine our knowledge and learning
from every corner of the world to distill it to one thing – the perfect solution for our client.
Research Capabilities
Subscription Information
 Customized Research
 Syndicated Research
 Investment Research
 Social Media Research
Sector Coverage
 Automotive and Transportation
 Electronics, Semiconductor, and ICT
 Retail and Consumer Products
 Industrial Automation and Equipment
 Chemicals & Materials
 Food and Beverages
 Services and Utilities
 Energy, Mining, Oil, and Gas
For detailed subscription information please contact
Hari. T (Sr. Manager - Global Business Development)
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268
Email: hari.t@futuremarketinsights.com
Customized
Research
Syndicated
Research
Investment
Research
Social Media
Research
2

Research Methodology (1/2)
Systematic Research Approach
In-depth secondary research is used to
ascertain overall market size, top
industry players, top products, industry
associations, etc.
FMI formulates a detailed discussion
guide to conduct expert and industry
interviews
FMI develops a list of industry players
(manufacturers), distributors, retailers
and industry experts
FMI conducts interviews with industry
experts, industry players, distributors
and retailers
Data is validated by triangulation
method, wherein secondary, primary
and FMI analysis contribute to the final
data
Data is scrutinized using MS-Excel to
obtain qualitative and quantitative
insights about the industry
FMI delivers industry insights and
information in the required format
(PDF)
Data
Collection
Data Filter
& Analysis
Research &
Intelligence
Actionable
Insights
Business
Solution
A
C
B
Primary
Research
Company
Analysis
Desk
Research
 Identifying key opinion leaders
 Questionnaire design
 In-depth interviews
 Coverage across value chain
 Market participants
 Key strengths
 Product portfolio
 Mapping as per value chain
 Key focus segments
 Key industry experts
 Channel study
 Developments
 Market dynamics
 Products
 Conclusions
SOLUTION
Primary Research#
 Linkedin
 Zoominfo
 Salesforce
 Avention
 Factiva
 GBI
 Genios
 Meltwater
 Company websites
 Company annual
reports
 White papers
 Financial reports
Secondary Research # Paid Publications#
Insights
Market profiling
Formulating discussion guide
Developing list of respondents
Data analysis
Data validation
Data collection
1
2
3
4
5
6
7
# includes sources of databases
3

Therapeutic Nuclear Medicines Market Analysis
4
Increasing acceptance of therapeutic nuclear medicines (or radiopharmaceuticals) among
industry experts will remain a prominent factor encouraging their adoption. Though
associated with a negligible risk factor, radiopharmaceuticals are likely to witness growing
recommendation owing to no proven significant adverse effects.
In the backdrop of the growing criticality of a more reliable, safer, and lesser harmful line of
treatment for cancers, therapeutic nuclear medicines are being increasingly perceived as the
potential treatment for cancer patients. Moreover, consistently surging instances of bone
metastases further supports adoption growth, in the therapeutic nuclear medicines market.
Just-under 10% Annual Growth Projected for Radiopharmaceuticals Adoption
A recent market research intelligence by Future Market Insights focuses on the deep-dive
evaluation of global therapeutic nuclear medicines landscape, emphasizing the analysis of the
most influential factors responsible for surging acceptance of radiopharmaceuticals in
treating a range of cancers and a few other chronic conditions.
Request a Sample of this Report @
https://www.futuremarketinsights.com/reports/sample/rep-gb-2930

5
The study projects robust progress for the global radiopharmaceuticals market in coming
years, reportedly driven by remarkable adoption in the treatment of prostate cancer. In 2019,
the global demand for therapeutic nuclear medicines is expected to grow at a 9.7% annual
rate, and maximum adoption is estimated by cancer research institutes at a global level.
 North America, jointly with Western Europe, represents more than 65% share of the total
market value.
 Outpacing developed regional markets, the radiopharmaceuticals market in China and
emerging economies across Asia Pacific, Latin America, and Middle East & Africa are slated
for higher year on year revenue growth of over 12% in 2019 and ahead.
 China is reportedly the most lucrative market for penetration of therapeutic nuclear
medicines, which is attributed to an expanding cancer patient pool in the country and a
consistently surging rate of radiopharmaceuticals recommendation.
Top Three Companies Account for More than 87% Market Value Share
A highly consolidated marketplace, global therapeutic nuclear medicines landscape is
dominated by Bayer AG that currently accounts for just-under 80% revenue share in market.

6
The top three players include GE Healthcare and Novartis AG other than Bayer, which
collectively cover over 87% of the total valuation of radiopharmaceuticals market. While
exceptional sales and success rate of Xofigo have been prominently retaining Bayer’s top
position in the global market, strategic acquisitions are identified to be the key strategy
behind Novartis’ success at a global level.
Get Full Report Buy Now @ https://www.futuremarketinsights.com/checkout/2930
Thorough assessment of the competitive landscape of global therapeutic medicines market
reveals a few prominent developmental strategies adopted by a majority of key companies
operating in radiopharmaceuticals landscape –
 Investments in R&D of targeted cancer therapeutics
 Stronger supply chain and more streamlined distribution network
 Improved flagship product sales
 Strategic collaborations with pharma/biopharmaceutical companies
 Contractual relationships with domestic/regional stakeholders

7
 Strategic deals with internationally recognized cancer research institutes
Over 20% Growth Forecast for Erbium-169
Radium-223 has been the highest recommended type of radionucleotide in
radiopharmaceuticals market. While it currently accounts for a whopping 78% share in the
global market revenue, it is more likely that Erbium-169 that has been witnessing higher
traction in recent past would witness relatively higher revenue growth in coming years. The
report forecasts over 20% year on year revenue growth for Erbium-169 in 2019.
Request for Report Ask A Question @ https://www.futuremarketinsights.com/ask-
question/rep-gb-2930
Exceptional Growth Projections for Thyroid & Brain Cancer
While over half the global market value is accounted by the adoption of therapeutic nuclear
medicines for treatment of prostate cancer, bone metastases also accounts for sizable
revenue generation in the market. Brain tumor and thyroid cancer are likely to emerge highly
lucrative targets for manufacturers of therapeutic nuclear medicines, according to the report.

Future Market Insights Global & Consulting Private Limited (FMI)
Thank You
To know more about us, please visit our website:
www.futuremarketinsights.com
For sales queries or new topics email us on:
sales@futuremarketinsights.com
For media queries, contact the press office at
press@futuremarketinsights.com
For other queries contact:
Hari. T (Sr. Manager - Global Business Development)
Future Market Insights: 3rd Floor,
207 Regent Street, London W1B 3HH
T: +44 20 7692 8790 | D: +44 20 3287 4268
Email: hari.t@futuremarketinsights.com
8

Therapeutic Nuclear Medicines Market Worth Observing Growth Top Key Player- Bayer AG, Novartis AG, GE Healthcare, Curium Pharmaceuticals, Eckert & Ziegler and International Isotopes Inc.

Recommended

Recommended

More Related Content

What's hot

What's hot (18)

Similar to Therapeutic Nuclear Medicines Market Worth Observing Growth Top Key Player- Bayer AG, Novartis AG, GE Healthcare, Curium Pharmaceuticals, Eckert & Ziegler and International Isotopes Inc.

Similar to Therapeutic Nuclear Medicines Market Worth Observing Growth Top Key Player- Bayer AG, Novartis AG, GE Healthcare, Curium Pharmaceuticals, Eckert & Ziegler and International Isotopes Inc. (20)

Recently uploaded

Recently uploaded (20)

Therapeutic Nuclear Medicines Market Worth Observing Growth Top Key Player- Bayer AG, Novartis AG, GE Healthcare, Curium Pharmaceuticals, Eckert & Ziegler and International Isotopes Inc.